Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 3Carcinoma, Hepatocellular 2Prostatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biochemically Recurrent Prostate Carcinoma 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Temozolomide 8sargramostim 2pembrolizumab 2Radiotherapy 2Radiation 2veliparib 1selinexor 1montanide ISA 51 1lonafarnib 1Vorinostat 1Sucrose 1Sonication 1Sodium Chloride 1Serotonin Antagonists 1Salts 1Photons 1Perfusion Magnetic Resonance Imaging 1Olanzapine 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1Loperamide 1Lomustine 1Irinotecan 1Granulocyte-Macrophage Colony-Stimulating Factor 1Drug Therapy 1Cyclophosphamide 1Colony-Stimulating Factors 1Carboplatin 1CLR1404 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gliosarcoma × Photons × Clear all
NCT05095376 2026-05-19

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NRG Oncology

Phase 3 Active not recruiting
265 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡